FRIDAY, October 17, 2003
Stem Cells: Recent Developments (Science and Ethics)
CHAIRMAN KASS: All right. We now move from the biotechnology
and public policy project to the monitoring stem cell project.
And this session we really have two staff working papers that we
The first is the ethical debates reviewed, and let me remind everybody
just very briefly what we're doing and what is this project.
We have been charged, and we are carrying out that charge, to monitor
stem cell research in the light of the current federal policy.
The task has basically three parts. First, a clear presentation
of that policy and its legal and ethical underpinnings to provide
a correct picture of the umbrella under which the activities take
place. A first draft of that was discussed at the last meeting.
It was not meant to be a defense, but simply an explication of the
policy as we understand it. There were criticisms offered, and
that—that document is being reworked.
Second, a monitoring of recent developments and moral argumentation,
as addressed to the moral, ethical, and legal legs of the current
policy. And, third, a monitoring of recent developments in stem
cell research and clinical application, adult and embryonic, publicly
funded and privately funded.
These three parts will be the basis of the shape of our report.
After an introductory chapter, a clear presentation of the policy
and its legal and ethical underpinnings, Chapter 2. Chapter 3,
recent developments in the ethical debates. And Chapter 4, recent
developments in stem cell research.
As this is a Bioethics Council, the first point of monitoring
is ethical, not scientific medical. The first question is: how
sound are the moral, legal, and ethical legs of this policy? And
that is the topic of—that's why the discussion of ethics here
is going to precede the discussion of science.
We, unlike other people who are engaged in this debate, and who
are engaged in it because they have interests that they are seeking
to defend, that they want what they want and they will lobby until
they get it, or they don't want what they don't want and
they will lobby to continue to oppose it. Our task here as an ethics
council really is primarily to consider what is the right and what
are the good things to do.
And we either could argue this through for ourselves, although
our opinions are as divided as the opinions out there, or we will
do what has—what we have decided to do here, namely to prepare
a working paper working toward a chapter that in fact is a review
of the current state of ethical argumentation pertinent to the policy.
And that is a very thorough staff paper with—based upon a very
thorough review of the literature over the last couple of years
is—is before you in Tab 9, "Monitoring Stem Cell Research:
The Ethical Debates Reviewed."
And I will read the paragraph on the first page of it. While
we—well, what this paper does is outline the general form of the
moral argument, noting that although other issues are certainly
also in play, the central issue is often turned on the moral standing
of the human embryo. Footnote to be discussed in a moment.
Second, we will discuss the specific questions and critiques regarding
the administration's policy as these have emerged in public
discussion. And we will have a continued discussion, too—of the
moral standing of the human embryos, seeking again to outline the
chief fault lines in that continuing debate.
"While we will raise these arguments and counterarguments,
problems, questions, and concerns, our purpose in this paper is
not finally to access the validity of the competing claims and to
arrive at a conclusion, but — in line with the charge to monitor
developments in this area — to present them more or less as
they have appeared in the public debates of the past several years.
"This way of proceeding has one especially prominent drawback:
it tends to present all arguments as equivalent in their importance
and prevalence. We will seek to avoid this whenever possible and
to offer some sense of which have been the key components of the
Now, I think that lays out fairly clearly what the style and the
spirit of the document is. The outline is, first of all, some interesting
remarks on the nature of the moral argument, a series of—a discussion
of the series of principles that are the moral bases of policy,
the relief of suffering, freedom of research, and the moral status
of the human embryo.
Then, arguments that bear on the character of the policy, whether
it's arbitrary, whether it's unsustainable, or whether or
not it's inconsistent. And then, in the larger section, discussions
of the moral status of the embryo with discussions about continuity
and discontinuity, and then a whole series of special cases and
exceptions, the IVF spares, the point about natural embryo loss,
the question of prediction of non-viability, and the creation of
possibly non-viable embryos, artifacts that might avoid this problem
I think this is not the session for line editing and going carefully
through this. This is well on its way I think to being the guts
of a possible chapter. And I think what's—what I and the
staff need to know from you is your overall impression about the
approach and the way of proceeding, whether there are important
matters left out, whether there are important issues misdescribed
in the language that we should be more sensitive to, and just get
your general sense about the document as a whole. Obviously, corrections
in detail in writing to the staff would be most welcome.
I would like to ask, since Alfonso prepared a memo which some
of you were able to get when I handed it out last night, but for
anybody who didn't get a copy of Alfonso's memo, there are
extra copies here. Elizabeth probably didn't get this. Anyone
else need a copy?
Alfonso has a number of things here, some of which have to do
precisely with the language, both of moral status and of the human
And perhaps, Alfonso, if you wouldn't mind—I don't want
to put you on the spot. But if you'd like to, for the moment
at least, deal not so much with your attempt to offer the proof
or the conclusion, but simply deal with the linguistic points.
DR. GÓMEZ-LOBO: Okay. I'd be happy to do both.
CHAIRMAN KASS: Feel free.
DR. GÓMEZ-LOBO: No. Really, the purpose of this
memo was precisely as I said, that it might save us some time.
So let me mention the linguistic point for a moment, and then, if
you're patient enough, I'd like to have at least one shot
at the—at a critical discussion of a concept that has played a
huge role in the Council it seems to me—the idea of an intermediate
And I think it's an untenable concept. That's why I think
it makes sense for me to make some critical remarks.
Now, the linguistic point is—that I see is this. Namely, that
it has become a fashion maybe for a decade or less to talk about
these things in terms of moral status. Earlier writers talked about
moral standing, but now almost everybody discusses it in terms of
And I think it's a very misleading expression, and expressions
easily divert our attention or mislead us into directions we don't
want to go. And what I do here is I call attention to the following—that when we think about status we have some model or other.
I mean, we don't think in the abstract.
And a possible model is immigration status. Maybe it's because
I had to deal with it for many years that I'm familiar with
it. And there are two misleading things about it, and, believe
it or not, it appears many times in the literature. Namely, the
idea that status is something that is granted.
Many writers talk and say, "Oh, we grant status to the fetus,
or we grant status to the child," etcetera. And I find this
misleading, because if anything this should be a property that something
has, not something that we arbitrarily assign or not assign.
I'm not complaining about the Immigration Service. They have
all the right in the world to assign a status, and it's an administrative
decision. But we should not be making decisions about a certain
category of beings. So that's number one what I find misleading
about the expression.
The second thing that is misleading in this expression is that
there can be immigration status of different kinds. You can either
be a temporary worker or you can be a resident alien or you can
be a foreign scholar. I mean, if you've dealt with the INS,
you know what I'm talking about.
And the problem, then, is that this suggests that there might
be different kinds of moral status, and that's where the other
problem comes in, that there might be something called full moral
status or non-full moral status or intermediate moral status.
And that that is—now we're going into substantive arguments,
if I cross the line here—if I may cross the line. But that's
also a misleading feature. If I ask myself, well, what is the—how has philosophy considered moral status in the past? Well, it
has considered it under the rubric of dignity, and the question
has been, well, does this object have dignity or does not have it?
Now this sounds a little bit harsh in terms of saying, oh, this
is, you know, a very harsh dividing line. But I think it is—I
think it is a very strict dividing line for the following reason.
Traditionally, the idea of dignity entails that you may not intentionally
destroy that being, or subject that being to instrumental use.
Period. In other words, to assign dignity, or Kant calls it the
value of persons, is to say that there is a being that is off limits
for any calculation for any balancing.
Innocent human beings should not be made an instrument, no matter
how noble the goals. That I think is the traditional idea, and
it—to me it makes a lot of sense, because I think that I can claim
dignity for myself and that I have to respect all of you, because
you have dignity.
Now, to the substantive point, is it true that there can be an
intermediate moral status? And to introduce my criticism, I'd
like to make an analogy with the idea of human rights. Now, for
instance, I'm sure we all acknowledge the right of defendants
not to be tortured.
And if we say, well, let's create an intermediate category,
the category of those individuals who sometimes may be tortured
to obtain confessions, let's say if there is tremendous threat
coming from whatever they have done. And someone might say, "Well,
this is an intermediate status, because we're not saying that
all defendants should be allowed to be tortured, but only this category
Now, if we do that, we're not really creating an intermediate
position, but we are really denying the basic human right to that
category of people. And this is for logical reasons, because the
contradictory of all is not none, but not some.
So, in other words, it's very important to realize that we're
talking about a property which on the one hand is the contradictory
of the assignment of human dignity, to say of any category of beings
that they can be destroyed under certain circumstances is simply
to deny dignity, not to say that they have less dignity. That's
the point I'm trying to make.
Now, of course the next question is fully an ontological question.
It's a question of how things are, not a moral question. Namely,
what is our relationship to human embryos? And what I do in this
memo is try to argue as simply as I can that there is a connection
of sameness. Namely, that there is continuity, but there is, above
all, biological sameness guaranteed or proven, let's say, by
sameness in DNA.
And that's why in the courts today DNA is used commonly to
prove identity or not identity between the defendant and the person
who committed the crime last month.
And then, I go on to say, well, it's not that we are only
our genomes, but our genome is a sufficient indication that we have
been the same biological individual through time.
Now, of course, there is the question of twins and—because twins
do have the same DNA. But in that case, spatial-temporal continuity
can be applied, and the alibi idea in the law has to do with that.
It's to say I cannot be the killer or the criminal, because
I was physically someplace else.
In other words, if you trace me in space and time back to that
moment, I'm not going to coincide with this person.
Now, that's very sketchy. But I wanted to have a chance to
put it forward, because so much hangs on this idea of an intermediate
moral status that at least we should think about it, it seems to
Now, the final point would be this—that to assign intermediate
moral status really entails contradictory moral commands, because
it seems to imply on the one hand that you may morally destroy something.
But on the other hand, since it's intermediate, it's not
an all-out predicate. You have reasons to protect that being.
And, of course, we cannot act on the basis of imperative that
bids us to do contradictory things. So those are, you know, in
very short summary, some of the key ideas.
CHAIRMAN KASS: Bill May.
DR. MAY: I feel Alfonso is presenting his credo, not directly
commenting on the debate of the last couple of years. And apparently,
this paper is attempting to describe the debate of the last couple
I don't mean to criticize Alfonso by saying that, because
as a matter or fact, is it possible to say that this paper is not
simply a description but in part an interpretation of the debate?
In which case I have a few comments to make about it, and about
the nature of moral argument as it is described here, and—
CHAIRMAN KASS: Let me make—let me sort of make the procedural
point, so we know what we're doing.
DR. MAY: Yes.
CHAIRMAN KASS: And I would I think concur, Bill, with
your first sense that that's probably why when I asked Alfonso
to speak to begin with the—there are two parts in his memo. I
mean, one has to do with the language of moral status and, although
he didn't comment on it, the human embryo. In fact, the whole
title of that subsection reads, "The Moral Status of the Human
Embryo." And Alfonso calls our attention to the problematic
character of both of those expressions.
If there are terms that are problematic, we at least who are propagating
those—promulgating those terms in this report should know about
it, and at least should call attention to the difficulty. The linguistic
point, therefore, addresses us as a Council drafting and describing
The substantive argument which he then tries to make is, it seems
to me, unless it's meant to say he is trying to put forth an
argument that ought to move this Council to a uniform conclusion
about it, it is out of line in the sense that it is not a comment
on the document, though now that it's a matter of the public
record the revision of this document can include that argument as
part of a critique of that—of the intermediate moral status view.
And we'd be happy to add.
So I would say that I take very seriously the terminological thing
as a warning for us. I take very seriously the moral argument as
something to be added to the document. And if there are other things
of that sort where important moral positions are not properly developed
here, we should have it. Or if there are misperceptions or misrepresentations
of the debate, we should have that as well.
But this is, I think, not the place to argue out, at least not
today, to try to argue out who is right and who is wrong on the
question of the—on the question—and whatever I'm going to
say is going to be—on the question.
I'm going to restrain myself, Alfonso, from enjoying a substantive
argument with you. If there's time, we'll do it later.
Bill, take the floor.
DR. MAY: The document, at the very outset, relies heavily
on the contrast between two metaphors—shaping moral reflection
on stem cell research, metaphor-weighing or balancing various contending
values or interests, and, in effect, the metaphor of trumping other
values by appeal to an overriding and unexceptionable principle
that demands the protection of a particular value such as the human
embryo, even against actions that might seem to realize important
Those who hold the latter view, as I understand it in this description,
would see it as inappropriate simply to think of the human embryo
as one more value to be placed on a scale of competing values.
The document, as it describes the debate, tends to associate the
word "principle" with the unexceptionable as opposed to
weighing and balancing in which it "may not really be clear
how this balancing actually takes place, and it may not be obvious
that there is any scale on which the various values can really be
Thus, the document refrains from describing weighers and balancers
as principle-oriented in their ethics. I sense in these remarks
the worry that unless one holds to a principle as unexceptionable,
one slides down the slope into the relative.
The document doesn't leave much room for pluralists and their
thinking about issues and ethics—those for whom duties are plural,
and, therefore, recognize that duties may sometimes conflict. Such
pluralism differs from both relativism and absolutism, perhaps more
than absolutism and relativism differ from one another.
On the face of it, absolutists and relativists seem irreconcilably
opposed. Absolutists agree—argue that the validity of a principle
depends upon its universality. There can be no exceptions. Relativists
have discovered exceptions, and, therefore, deny the principle.
At a deeper level, however, absolutists and relativists agree.
Both subscribe to the view that the validity of a principle depends
upon its universality. The value of a good, the heft of a principle,
depends upon its supremacy, its overridingness in all circumstances.
Neither has discovered the wisdom of the ancient observation that
moral principles/laws are true for the most part. "For the
most part" is not a loophole in and through which one escapes
into the sea of the relative. They are true for the most part in
the sense that they reach their territorial limit in those cases
where they must yield to another principle or good. The more stringent,
the more urgent in a particular case.
Further, even in that yielding, the original principle does not
simply vanish. It maintains pressure upon one, and how one pursues
the supervening good, and it generates in some cases duties of reparation
and gratitude for losses imposed and benefits received. Such is
the rough landscape of policy-making in which one may need to compromise,
not in the sense of defecting from duty but honoring duties which
CHAIRMAN KASS: That's a beautiful statement, Bill,
and I think—I won't even allow any objections.
I mean, I think the document has to include that as—as at least
true of some people in this moral debate. Wait a minute.
PROF. GEORGE: But as with all views presented, the counterarguments
will be presented as well.
CHAIRMAN KASS: Well, no, no, just a minute. You want
to say something to that?
PROF. GEORGE: We can have the debate now, if you'd
CHAIRMAN KASS: Just to that.
PROF. GEORGE: Yes, okay. What are some examples of fully-specified
DR. MAY: Well, you ask for an example. I spent a weekend
at an institution for retarded folk, when I was in a chair at the
Kennedy Institute of Ethics. And the folks that ran that taught
us wrestling holds that they use with the retarded, some of whom
on special occasions their difficulties take the form of doing damage
to themselves or damage to others.
And they have a basic commitment, of course, to liberty in how
they treat people there. On the other hand, when they're doing
damage to others or themselves, the tendency of course is to toss
them in the slammer or put them in a straitjacket, and then you
turn away from them and to other things.
And by teaching them wrestling holds, they pointed out to the
staff members—in effect, they teach them how to make a straitjacket
out of the body of the retarded person, holding them by the wrists
behind their back. And it guarantees that people will not hold
them any longer than is necessary, whereas if they are in a straitjacket
they are put on hold and forgotten.
Now, there you have two duties that run into some tension with
one another—the duty to protect people from harm; on the other
hand, the duty to honor liberty. And at that moment, the duty to
honor liberty yields to the duty to protect. But it doesn't
simply vanish; it affects how you protect, and that you don't
impose the curtailment of liberty any longer than is necessary,
and so forth.
And as I went through that experience with those two women who
were teaching me those holds, I realized what a lovely parable it
was for the difference between the tyrant or simply the person seizing
power who takes the excuse of the crisis for imposing restrictions
and doesn't think through you do the least restriction possible
for as short as possible a time, and so forth, only when it is a
Now, it's that kind of specification that I think is important.
And you don't have an absolute that trumps in any and all circumstances.
And if it fails to trump, then quickly things unravel into the relative.
That would be one illustration.
CHAIRMAN KASS: Do you want a very quick -
PROF. GEORGE: Yes. This—
CHAIRMAN KASS: Not a long—
PROF. GEORGE: Okay. This may be, you know, a difference
in the way two different schools of philosophical analysis approach
a problem. I think we'd come to the same conclusion, but—in this particular case as to what ought to be done.
But I certainly wouldn't want to analyze it in terms of conflicts
of duties, because once we have the circumstances and the norms
that apply fully specified, I think that we see we have a particular
duty here. There's not a competing duty. There are various
principles, there are values, that are at stake here that have got
to be honored.
But at the end of the day, the duty is to protect the child.
The duty is to do what is in the best interest of the child. Sometimes
that will require respecting the child's liberty, and in that
case we can talk about a duty to respect. When fully specified,
that's the conclusion to the normative syllogism.
In other cases, we'll say that our duty is to restrain the
child, not to respect the child's liberty. It's not that
it conflicts with the duty of liberty.
DR. MAY: You're talking about actual duties. But
it seems to me the language of the description of the debate tends
to suggest that either you have unexceptionable principles or you
are engaged in a weighing and balancing, and that's a very slippery
And I try to suggest ways in which one simply doesn't have
the alternative, engaging in a weighing and balancing that lacks
any sense of principle. And the one sentence that I quoted I thought
moved in that direction.
CHAIRMAN KASS: Gil.
PROF. MEILAENDER: These are complicated matters, though.
I'd have to look back at exactly what the document says. But
the—and I actually would come at it in—Robby has a particular
system out of which he comes at it, and I would come at it in a
little different way.
But the question is not whether all duties are without exceptions,
and you're just stuck when they clash. The question is how
you resolve circumstances in which you appear to have competing
And there are ways of resolving them through building in exception
clauses, or through lexical rankings, and so forth, that do not
involve weighing and balancing. The question is whether the competing
duties are—what seems to be the competition between the duties
is resolved by some sort of weighing and balancing of consequences
That I took to be the alternative, and I don't think I—I
suspect that, Bill, your description would not necessarily want
to suggest that the—this clash between prima facie duties is resolved
by weighing and balancing. But there are various ways to do it,
and they do not have to involve a turn to a metaphor like weighing
CHAIRMAN KASS: Rebecca.
PROF. DRESSER: This is related, to some extent—I didn't
see anything in this document discussing the special respect position
and how—the implication seems to be if the special respect position
is taken, then there is no scrutiny of the reason why embryos are
going to be used and stem cells are going to be taken.
But within the—I think some of the argument that's going
on in our culture today is, what does special respect mean? And
so a system that builds on that view could be more or less restrictive.
There's a lot of room in there. And so it shouldn't be
seen as, well, unless you adopt the view that the embryo is equal
to the born person, then there's no scrutiny at all. And so
it seems to me it should at least be acknowledged that there is
CHAIRMAN KASS: There should be a richer presentation of
PROF. DRESSER: —and we're not sure where to go with
CHAIRMAN KASS: Very good on that, yes. I mean, we will
do that, and we will also incorporate something of Alfonso's
view that the doctrine is altogether incoherent.
DR. GÓMEZ-LOBO: Yes. That was my request. Well,
let's do it. I mean, let's see what that special respect
entails, because I—my own feeling is, once we get down to it,
something similar to these other cases is going to have—
CHAIRMAN KASS: Rebecca, if you'd like to—I don't
want to lay any work on you. But if you give us a paragraph or
two as to how that would look, and you'll send it to him, and
PROF. BLACKBURN: I was thinking about the second part
of what Alfonso had presented, and the argument about same DNA providing
a reasonable criterion for biological sameness and the recognition
of sameness. And I think this really pertains very much to the
discussions about cloning that we had earlier, which is the issue
that if one does have an adult cell which has, of course, the DNA
in it that will become the same DNA in the, say, cloned blastocyst
for producing stem cells for biomedical research.
For example, and that's the same DNA, and then one has to
get very arbitrary as one considers the DNA in, say, the adult skin
cell that is used for the source of what gets put into the enucleated
oocyte—or egg, sorry, and then into, say, a cloned blastocyst.
And so, really, it's very hard for me on any sound basis to
say suddenly something magical happened during any of those particular
CHAIRMAN KASS: I'm sorry. During?
PROF. BLACKBURN: During the steps of the skin cell genetic
material, DNA, going through the process of an enucleated egg, and
then becoming a blastocyst.
So I think that there's a problem in that argument, and what
it would—the corollary of it is that if we don't think an
adult skin cell is anything special, then I don't think it—you know, then a cloned blastocyst, by logic, is equally not something—it hasn't created a new genotype that's unique to that
individual. It's simply the old genotype of the original donor
of the cell.
So I think that's just a logical corollary of this argument,
and it does take us back to the—
DR. GÓMEZ-LOBO: Can I add something briefly? My
claim is that the DNA provides one criterion for sameness of an
organism. I mean, surely we don't want to say that the skin
cell is an organism, right?
PROF. BLACKBURN: Well, I think there's a continuity
where it's very hard to suddenly say something happened at what
moment. So I think there's a real difficulty in the continuity,
and it's very hard to say suddenly something happened.
DR. GÓMEZ-LOBO: Well, I've been listening.
Scientists tell me that something very important happens when you
have the syngamy in the case of natural fertilization or this reprogramming
in the case of selective cell transfer.
PROF. BLACKBURN: Yes. And that's a continuous process.
It's not in a sudden moment. It's a continual unfolding
saga of events. The reprogramming is a continuing event. And I
think it—and I think we also in that line—the potential of this,
which is the other kind of nature of the argument is, you know,
as Rudy Jaenisch very clearly pointed out, this does not have the
potential to produce a normal individual, and as we've discussed
in the line of the clonote.
So I think that, logically speaking, one could come to the conclusion
that the clonote is, you know, no more of an individual than the
DR. KRAUTHAMMER: But our experience is that a continual
process does end in a discontinuity named Dolly. So you end with
a discontinuity with another being. We can argue about when the
PROF. BLACKBURN: Yes. I was really arguing for cloning
to produce blastocysts, and not for going on to reproductive cloning.
I'm not arguing that one should go forward to reproductive cloning.
DR. KRAUTHAMMER: All right. But at some point you recognize
that that process, which you call continuous, if allowed to continue
results in a discontinuity.
PROF. BLACKBURN: If allowed to go to reproductive cloning.
DR. KRAUTHAMMER: Right.
PROF. BLACKBURN: Yes. No, I really was confining what
I wanted to talk about—
DR. KRAUTHAMMER: Okay.
PROF. BLACKBURN: —to the idea of producing blastocysts,
the biomedical stem cell research issue.
CHAIRMAN KASS: Well, I'll subside on this. We could
discuss this further, Elizabeth, but I don't think—there's
a question about whether continuous biological processes, they don't
also result in some kind of novelty at a certain point. Whether
you then go on to use the cells for research or not would be a separate
and additional question.
PROF. BLACKBURN: But the DNA is the prime source I think
Alfonso is raising, and I'm saying it's one in the same
DNA. That's all.
DR. GÓMEZ-LOBO: But this is just—I'm just
saying this is just a criteria to judge sameness across time of
a given kind of organism.
CHAIRMAN KASS: But the sameness of DNA is not the—is—
DR. GÓMEZ-LOBO: Is an indicator.
CHAIRMAN KASS: It's an indicator, but it's not
the sufficient criteria of what you're talking about.
DR. GÓMEZ-LOBO: No. No, indeed. And then, the
interpretation of what Rudy Jaenisch said, I mean, maybe this is
not the point to discuss it, but -
CHAIRMAN KASS: And he didn't say absolutely. He said
almost. I mean, there were qualifications in there, and he certainly
can't know for certain that we won't get a Dolly—you know,
a Dolly on—
PROF. BLACKBURN: If one does an implantation into a womb—
CHAIRMAN KASS: Yes, sure.
PROF. BLACKBURN: —I mean, it takes a lot more than just—
CHAIRMAN KASS: Let's leave this alone and go on.
PROF. MEILAENDER: Yes. Interesting as these things are,
I did take it that the purpose of this paper was not to argue the
CHAIRMAN KASS: Correct.
PROF. MEILAENDER: But to try to outline the argument.
And I just wanted to make two comments with respect to that.
One is just taking the document as it is, one comment about its
structure. I think it's—and I'm not sure I'm right
about this, but it seems to me that it's peculiar to find the
discussion of IVF spares at the point in the document where we find
The point in the document where we find it is within the discussion
of the embryo and the disagreements about the embryo, because the
thrust of the document has been to say it just turns out that that's
where people disagree, and so we're going to discuss the embryo.
But the IVF spares are embryos. It's just another case of
the same disagreement appearing. If you think that those embryos
are human subjects, possibly even dying human subjects, you think
they should be treated in one way. And if you think they're
not, they should be treated in a different way.
So it seems to me that the spare issue should—it's not that
it shouldn't be discussed, but it shouldn't be discussed—we should find a different place in the document for it. That's
CHAIRMAN KASS: I'm not sure I understand the nature
of the objection to its location.
PROF. MEILAENDER: Well, it's not—the discussion
of the embryo is a discussion about all of the different points
at which people have suggested that there is a moment of discontinuity
that might be thought of as a beginning point.
But that's not the issue with the IVF spare. The issue with
the IVF spare is kind of, what should you do with this thing, whatever
you happen to think about it. It just seems to me it's a different
question, and it's mislocated.
CHAIRMAN KASS: But it's—well, rather than argue
it through here, let's—we will take that up, but—
PROF. MEILAENDER: Yes, I'm—in fact, it's not
something I'm going to go to the wall for or anything. It's
just a suggestion.
CHAIRMAN KASS: Okay.
PROF. MEILAENDER: The other thing is—and this is just
a comment, and I'd—and if anybody—anyone else has views
on it, I'd be interested in hearing—if you're trying to
summarize the debate, I admit I have a hard time thinking of other
or better ways to do it than the way the draft document does. But
there is a kind of dizzy quality to it, you know.
Some say—critics say this. You know, you're sort of back
and forth, back and forth. I'm not sure how good a read it
is in a certain sense. I don't have a particularly good alternative
to offer, but I just wanted to sort of note that in case others
shared the view and I could trigger a better suggestion.
As I say, there may be no better way to do it. I'm perfectly
prepared to accept that possibility. But there is just sort of
a swaying to and fro quality to it that at some point is dizzying
CHAIRMAN KASS: Do you want to respond to that?
PROF. DRESSER: A little. I wanted to—if I were a teacher
marking this up, I think it needs some more head—clearer headings
and topic sentences and thesis paragraphs.
CHAIRMAN KASS: Right.
PROF. DRESSER: I did have a sense as I was reading through
that it wasn't as easy to follow as we would like our—but
I assumed that that would be cleared up.
CHAIRMAN KASS: Yes, we will work on that. But could we
deal head on with Gil's suggestion that, you know, this is—it's partly an attempt to be faithful to the argument without
ourselves taking sides, which produce—and it is—we will try
I think to not simply treat everything as equal to—every argument
as equal importance to everything else. So we'll give some
kind of emphasis.
But we are going to be stuck with on the one hand and on the other,
and, as Gil says, he hasn't—he doesn't yet have a suggestion
for how to do this better. The alternative, of course, is on the
one hand, on the other we say—I mean, you know, the method of
But I think I've been in this room long enough to know that
we say on the one hand—
—therefore, we do a kind of service. And by the way, this, I'd
be willing to say with your consent, that at the end of the day,
after having laid this out one side or the other, one of the things
I think we can say is that if anybody thinks that this debate has
now resolved itself so that we can sort of settle this question
once and for all, and pronounce that this side is victorious, they
No one, it seems to me, with a fair reading of this—and I think
this is not a bad conclusion to set forth as monitoring the argument.
The argument has gone on before the President's decision, it
continues to go on, it will go on from here forward.
But we don't find anything at this point that would lead someone
to be able to say that decision is—conclusively that that decision
is wrong, or to say conclusively to the contrary—in other words,
that—to indicate that this—that what we've done here leads
to a certain kind of conclusion.
Now maybe—I see there are people reaching for their electronic
equivalent of revolvers to shoot down that suggestion.
So let's have it.
PROF. MEILAENDER: Well, what would that mean, if we said
that would—would that mean that none of us was persuaded that
one of the arguments was good enough that somebody should adopt
it? I mean, that would seem to be a peculiar place to arrive.
CHAIRMAN KASS: Yes, okay. One bullet.
Does someone want to respond to the question of the form? I mean,
it's a problem I think to do other than what we've done.
PROF. WILSON: I think—I'm not certain about this—that we're reduced to a choice between two forms. Form A
would be people on one side of the issue, assuming we can identify
clearly two sides, possibly there are three, stating at length all
of their arguments. And the people on the other side, or possibly
a third side, stating at length all of their arguments, and we put
The disadvantage of that process is that the arguments on each
side will not be fully met. And we will be forbidden in effect
from correcting the language of the side we're not on, because
it is, after all, their side. And, therefore, the value of this
document, which I think is very large, will be lost.
The other way is to say here, with respect to each stage, are
a series of arguments, and here are their corresponding rejoinders
matched up as accurately as we can possibly make it, subject to
review and criticism by all of us. This gives the kind of seesaw
quality to it, which I think is: a) inevitable, and b) desirable.
CHAIRMAN KASS: Robby.
PROF. GEORGE: Leon, one of the questions that has interested
me as we've touched on issues in this debate over the time the
Council has been in existence is the question of where our disagreements
are. And I think that this paper is useful in clarifying that.
But there is one area in which I'm still not quite sure whether
we have disagreements, and that is the area of embryology and early
human development itself. I'm not sure to what extent our disagreements
presuppose a common understanding of embryogenesis and to what extent
there is actually dispute.
Michael Sandel and I had occasion to debate this issue of the
standing of the embryo at the American Political Science Association.
And I thought it was very—a very useful debate, because we were
able to pinpoint where our disagreement was because we did agree
on the underlying embryological facts. And then we got to a point
of moral disagreement or the interpretation of those facts in view
of moral principles.
But I'm not sure in every case whether there is that agreement.
I'm not sure if Dr.—if Mike Gazzaniga would agree with me
or with Michael Sandel on the embryological facts. There have been
things that he said in the course of our deliberations that leads
me to think that there might be a disagreement there. That's
not addressed here, and I wonder if it could be.
CHAIRMAN KASS: Okay. We have two choices here. We've
got three choices—A, B, and A plus B. A would be to explicitly
introduce into the discussion, although it's tacitly here on
the question of continuity and discontinuity, we come close to the
question about what the truth of the embryological situation is.
But we could add a section here to indicate that there might be
arguments on the embryological facts.
I mean, Michael I think was—Michael Gazzaniga was exaggerating
rather luridly to make a point in a very early meeting when he declared
the early embryo to be the equivalent of lumber at Home Depot, or
something like that. I don't think if—I don't think if
he was going to write a dissent to this document he would sort of
describe it that way.
But alternative B is already in the works, which is we have an
appendix to this, which is a kind of little primer on the embryo.
That is to say, what thoughtful citizens should know about the embryo,
so that they can actually enter into this discussion.
And that's partly embryological facts and partly shaped in
a certain kind of narrative way, so that we're not simply going
to—so that's B. We could do both.
PROF. GEORGE: Well, if there's actually not differences
of opinion that are significant, then I suppose it's not critical
that it be up front. If there are—
CHAIRMAN KASS: Well, why don't we try -
PROF. GEORGE: —it would be more important.
CHAIRMAN KASS: Well, it's, it seems to me, less important
amongst us, then, to see what's in the literature on this question.
And we can certainly—we can be in touch with Mike Gazzaniga to
see if he wants to make an issue out of that as a comment on this.
PROF. GEORGE: In fact, maybe it would be good to check
with others who—with Janet and others who aren't here, just
to see whether that's an area where we do have disagreement
CHAIRMAN KASS: Yes. Okay. Will do.
PROF. DRESSER: I would prefer and favor the approach that
this takes of working through arguments rather than one side versus
the other side, because I do not think there are two sides and sort
of a split on one issue. I think there are lots of complicated
things to think about, and I would rather explore this discussion
in its richness.
On that note, on the second-to-the-last page, 26, it mentions—this is the catch-all where all of these other considerations
are mentioned. I would like to add that toward the bottom it's
talking about the discussion on the likelihood of cures, and so
To me that concern is tied to the principle of truth-telling.
That is, we should discuss this research in a way that is reasonably
accurate, and just as we are—we have decided we should tell patients
the truth about a depressing prognosis, in a sensitive way we should
also tell people the truth about the status—not the status, the
preliminary nature of this research.
So I'd just like to see it tied to a broader principle of
truth-telling, which I think is important in medical ethics and
And then, the one right below there, the disproportionate emphasis
is tied to justice considerations and priority setting and some
of the things that Dan Callahan has written so well about. So,
again, there is a broader concept and ethical consideration that
I'd like to tie these points to.
CHAIRMAN KASS: Excellent. We will do that, and we'll
consult with you on how to do it, and to do it well.
I take it from the discussion that there's a general endorsement
of the form, recognizing its limitations, and that we will, in fact,
make it clear that we—maybe even make it more explicit why we've
chosen this form, and also provide the kind of more helpful structure
to help the reader through this on the one hand on the other, and
reconsider the placement of the spare embryo question, take into
account Bill's very rich discussion.
Am I leaving out—take into account Alfonso's concerns on
the terminology, make at least—in fact, make—have a discussion
here rather explicitly on terminology, which we haven't so far
done, and add the exchange between the special respect and the response
on the special respect to fill out that discussion to make this
a richer and truer account.
Robby, anything else?
As you can see, I'm trying to—I mean, there are large things,
we should have them. If they're editorial things, we'll
get them in writing. But I'd like to move on to the other paper,
so that we can get through the meeting.
PROF. GEORGE: Leon, if I can just hold us one more minute
CHAIRMAN KASS: Please.
PROF. GEORGE: —this paper. Section 4(d) raises the issue
which Bill Hurlbut brought to our attention in his statement. This
is page -
CHAIRMAN KASS: 24.
PROF. GEORGE: —24, which Bill brought to our attention
as a possibility in his statement attached to our cloning report.
This I think is of particular relevance. It's something that
those of us who take the high view of the standing—of the embryo
are really interested in. Some of us—of course, some members
of the Council believe that embryo experimentation, under certain
circumstances at least, is morally acceptable.
But those of us who don't think that, or at least don't
think that we should pursue research involving the destruction of
embryos, wonder whether there may be a way out of this dilemma by
the creation of entities possessing a human genome and capable of
yielding useful material, such as embryonic stem cells, but which
lack features which would lead us to conclude that these are human
beings in the early stage of development, strictly speaking human
I think it's great that it is taken up in this paper, but
it's at a very early stage of discussion. And I have a concern
that just the way it's presented here it may suggest that what
those of us who are interested in this are interested in is the
creation of embryos that are then interfered with in a way to ensure
their early aborting, or something like that.
Now that's not actually what those of us who are interested
in this are interested in. We're interested, rather, in the
creation ab initio—the possible—of a possible entity, which
would, by our account, not in fact be a human being. I think this
is a very worthy thing to explore, but I would be happy if we could
work with the staff—
CHAIRMAN KASS: We'd be happy to put this language
in the form that is acceptable.
PROF. GEORGE: Great.
CHAIRMAN KASS: Are we all right on this? Michael, is
PROF. SANDEL: Well, this is a possible alternative structure,
but it may not be a good idea. It may be that we should just give
a catalog of the arguments on both sides. But if we wanted to have
a more focused paper that probably would have more of an impact
certainly within bioethics—I don't know whether the public
would pay attention or not.
There are really two interesting questions, two interesting philosophical
questions posed by this issue. One of them is the one that Alfonso
raised, the moral status and the moral standing of the embryo, and
that debate. The other one is the question of the relation between
one's view about the moral status or standing of the embryo
to policy, and specifically the question raised by Peter Berkowitz's
commissioned paper for the Council, whether if Alfonso is right
about the moral standing of the embryo, is it a defensible position
to ban the funding, never mind the timing and the date, to ban the
public funding but to permit the private use of stem cells.
That's an interesting question, without getting into—but
it's also a question on which there may be agreement—there
might be controversy about that, but the controversy would probably
not cut along the familiar lines defined by the first question.
In fact, I suspect that Alfonso and I would probably be on the same
side of that second question, and that I think would be—we got
a little bit into that when we were discussing Peter Berkowitz's
And so one way of making a contribution of a more pointed, distinctive
kind, rather than cataloging all of the arguments on one hand on
the other, would be to take that central issue as the question,
to argue it out, and to look at the arguments on both sides about
that, about the relation between one's view of the moral status
or standing of the embryo, and a policy that would prohibit the
use of federal funding but would permit the practice with private
CHAIRMAN KASS: Alfonso, do you want to respond?
DR. GÓMEZ-LOBO: Yes, very briefly. I think that's
a very important question. But, of course, the other one is the
prior one. I mean, unless you philosophically—
PROF. SANDEL: We'll do both. So a document that sort
of reflected—and we would have to hash out both. Here we could
draw to some extent on what we've already done, and that would
be—that's the interesting bioethical, philosophical—those
are the two interesting questions.
CHAIRMAN KASS: I'm not sure whether, without thinking
about it, I want to concede that those are the two interesting,
you know, questions. But my sense is that: a) we have a certain
interest in getting this document out before the science that it
is based upon is simply superseded.
And I also think that we do do a service in the way of monitoring
the debate to organize it. I mean, to really—the literature has
been widely combed and covered. We've organized it I think
in a very helpful way, however incomplete and however much it could
be enriched. And, you know, one owes people an account of, you
know, what the live issues still are, maybe giving some greater
emphasis, and perhaps, Michael, adding the point that you raised.
Peter Berkowitz's paper will be in the appendix as one of
the papers that was prepared for this project. And if you or someone
else would be interested in—that would be a place to do this,
to have a kind of additional paper on the second subject.
PROF. DRESSER: Wasn't the staff paper we discussed
along with the Berkowitz paper addressing some of these questions?
CHAIRMAN KASS: Yes. The staff paper will be the second—that was—that will turn into the second chapter where that question
will in fact be discussed.
PROF. DRESSER: So maybe that could be expanded to—
CHAIRMAN KASS: And that could be expanded as well. I
think, unless somebody has something late to say, I think we understand
pretty much what we have to do, and we will do it. Timetables for
next stage is to be worked out after this meeting. There are too
many balls in the air to try to do this on one leg.
If you're willing and not too tired, and I know some people
have early departures—we have only one person signed up for public
comment, and I think we could probably do this—the next paper
in half an hour, 45 minutes tops.
The second of the staff working papers is called the "Application
of Human Stem Cells in Research and Medicine." And I want
to put this paper into context as well.
You will recall that we've commissioned five, six, seven—seven research papers. I think that's right—five on the stem
cells of various sorts and varieties, one on the immunological suppression,
and I think another one from Dr. Itescu on which topic now escapes
me. So there's seven of those.
This paper is to be understood in the context of those papers,
which will appear in the report.
The second thing to say about it is it doesn't attempt to
summarize those papers. It attempts to be an additional contribution,
and I think a contribution of real interest. It needs I think some
revised introductory material to help the reader who has just come
out of the ethical discussion get into the scientific discussion
with a little greater explanatory and narrative clarity.
But what it attempts to do, and I think something quite important,
to discuss something which has not generally been discussed in these
matters before—namely, the whole problem of getting reproducible
results using these preparations and their derivatives and the various
kinds of issues that are attached to it, a discussion on pages 2,
3, and 4, with summary toward the bottom of page 4.
Then, a brief review of—with a couple of best studied cases
of the exemplary human adult stem cell preparations, and then beginning
on page 7, going through page 8, and top of page 9, a brief synopsis
of the human embryonic stem cell preparations. Well, human embryonic
stem cell preparations, the cloned embryonic stem cells, and the
embryonic germ cells.
And then, just a brief comment on basic research, but then a contribution
that I think the public would very much welcome, which is some discussion
about how stem cell preparations might, in fact, be used to treat
diseases, a question of—what is the situation with respect to
the problem of immune rejection, and then a particular case study
of considerable importance and human interest—the treatment of
Type 1 diabetes.
And current therapy and choices, stem cell therapy for Type 1
diabetes, and then some conclusions about where we are, the conclusions
stated on page 13. And I think what we mostly want here—Dick
Roblin is responsible for the work on this. He has had consultation
with Elizabeth, with Bill, with Janet, and we can get additional
reviews on the science.
The question here is not the accuracy of the scientific detail,
but a more general comment on the chapter, understanding that it
will be—there will be some additional material sort of at the
beginning to help people get into it.
PROF. WILSON: I am not gifted at reading these scientific
documents, and I read this document twice, and I don't understand
a word in it because it is written so exclusively in medical terms,
with which I am unfamiliar.
I will give you some examples if you want, but I would be happy
to pick them at random.
Now, if we're addressing an audience other than physicians,
who clearly will understand this, we have to convert a lot of these
terms into language that a non-physician audience can understand.
And this requires rewriting the whole thing from beginning to end
with lots of explanatory definitions and the use of commonplace
words suitably defined that refer to things that are otherwise referred
to simply in physician language.
This is a big job, but I think the paper is of sufficiently great
value that it's a job worth doing.
CHAIRMAN KASS: Is Jim's view shared amongst the non-scientific
members of the group? Do people have similar difficulties? It's
not just that he's a social scientist.
PROF. WILSON: I would not be surprised that I'm the
only person at this—
—but the country is filled with a lot of people who are like
CHAIRMAN KASS: Would that it were true.
DR. HURLBUT: I felt the same as I read the document, even
though I know the words. And it did strike me that at the very
least we might add a glossary to our—
CHAIRMAN KASS: There is going to be a glossary.
PROF. BLACKBURN: I'm coming at it somewhat differently,
with the idea that in the many, many trees that Dick has so competently
and thoroughly outlined, we weren't getting a distillation of
the forest here. And whether that is put up front or at the end
is very important, because this is just on the foreground. There
might be more about this, because I do have some other suggestions
which didn't relate specifically to this issue. So shall I
hold them until others have addressed this particular aspect?
CHAIRMAN KASS: I think the—to make this general reader-friendly
is an exhortation which will be followed. And it's certainly
doable. I mean, these are complicated things, so you can't
simply water everything down. But I think we can provide help with
the terms, a certain kind of clarification of what the issues are
before one gets into them. And I don't think it's that
Still on this point, before Elizabeth goes somewhere else? Gil.
PROF. MEILAENDER: I didn't think it was as bad as
Jim suggests. I mean, there are a lot of sentences in it that I
understand perfectly well, in fact. I mean, I just looked at one
here—rats paralyzed by a virus-induced nerve cell loss recovered
partial motor function after transplantation with the human cells.
No problem. You know, that's fine.
PROF. SANDEL: That's only because they showed us a
video of those rats who are—
PROF. MEILAENDER: It did remind me of that. It did remind
me of that.
PROF. GEORGE: There's another intelligible sentence
on page 10.
CHAIRMAN KASS: Come on, guys. Let's stay on point,
PROF. SANDEL: And at the time you thought those rats were
hobbling pretty badly.
CHAIRMAN KASS: They're now trying out for the Lakers.
PROF. MEILAENDER: The problem is that there are other
terms that, again, I'd be happy to see it made more user-friendly,
that I'm not sure can be replaced. I mean, you know, so I just
look down—I see lymphocyte.
The problem is that the non-scientific reader has to remember
from one sentence to the next what lymphocyte is. You know, you
can tell yourself what it is, but you have to remember it. But
there may be no replacement for it, so, I mean, I just—I don't
want us to hold out unrealistic possibilities for what can be done
here. I think that there are a lot of terms there aren't any
CHAIRMAN KASS: Right. Still on this same point?
Elizabeth, please continue where you would like to go.
PROF. BLACKBURN: Well, I think that the big issue, if
we're trying to inform the public about the situation as it
stands now, is that there's a big gap which isn't explicitly
addressed. And that is that nobody has done a side-by-side analysis
of human embryonic stem cells and human adult stem cells in a side-by-side
way, which isn't encumbered by commercial pressures and isn't
encumbered by even, you know, polarized arguments.
And that's something that so clearly I think would belong
in, you know, the public funded realm that I think that the public
reading this would think that such comparisons have been done.
They haven't. And those arguments about which is best for what—every time you hear these arguments you know that the person making
them is very much, you know, for their own either scientific passion
or for the—or for commercial reasons. We're getting only
one side of the story.
And so I think publicly funding honest side-by-side uncommercially
encumbered comparisons for certain things is really sorely missing.
And you can't make—you know, talking about truth-telling,
how can they be told the truth when we don't even know what
the truth is, and there hasn't been a mechanism to find it out
in an unencumbered way.
CHAIRMAN KASS: We can certainly make that point. We can
make that point very clearly.
DR. MAY: I understand the desire to make it more accessible
to the general reader. But at the same time, I think, as it bears
on the whole of what we do, the scientific community will be wondering
whether we are—
CHAIRMAN KASS: We know our stuff.
DR. MAY: —fully cognizant.
CHAIRMAN KASS: Right.
DR. MAY: And so we cannot sacrifice accuracy about that
for this question of general readability.
CHAIRMAN KASS: Absolutely.
PROF. BLACKBURN: I think distillations and sort of distillations
of sections of it, that the reader can—you know, like executive
summaries. You put the main point at the beginning, and then you
go into great depth.
CHAIRMAN KASS: Yes.
PROF. BLACKBURN: And I think those can be done effectively,
you know, without—it's carefully done without too much loss
of accuracy. I agree it's tricky, but I think it could be done.
CHAIRMAN KASS: We can do it. We can certainly do it.
General agreement that the aspiration of this chapter, as an addition
to the several review essays, what it tries to do—I mean, I think
the fact that there's a kind of case study and that one has
to—enables people to see what all has to be done before this can
be successful I think would be—is a very useful contribution.
And also, the materials about the reliability of getting reproducible
results from reliable preparations, and some of those difficulties.
I think there is just a lot of confusion out there about how easy
this is going to be and how quickly it's going to be accomplished.
And also, the point that Elizabeth makes about the importance of
actually getting the data and finding out the truth about side by
side and these sorts of things would also be—
PROF. BLACKBURN: Which relate to that point of we don't
CHAIRMAN KASS: Exactly.
PROF. BLACKBURN: —easy these things are, because we keep
getting viewpoints about this, which I—
CHAIRMAN KASS: All right. Could I—let me indulge myself
for one moment to ask Alfonso one question from the last session,
and we'll have our public comment.
On hypothesis, just so that I can go away and think about this,
I know you think that dignity is a term referred to human beings,
and you give Kant as your source, and we can argue about all of
that on some other occasion, but—and that there is, therefore,
If granting a hypothesis that we regarded an oak tree as having
dignity sub five, not human, and that you don't cut down oak
trees with impunity save when they're either going to spread
disease in the neighborhood or are going to fall down, would the
argument then mean that the acorn was, by virtue of continuity,
DR. GÓMEZ-LOBO: Well, it's a very loaded question,
actually, I think.
CHAIRMAN KASS: But it has to do with the continuity question,
and I don't want to—you know, if you could reject the example
DR. GÓMEZ-LOBO: No, I love the example, because
we've been struggling with it I think. Well, there are two
different things. There is—one is the question of continuity;
namely, whether an acorn is an oak tree.
Now, it seems to me that I don't know my botany very well
here, but—and this argument has been made to us a number of times.
It seems to me that an acorn is not an oak tree if, by oak tree,
we mean something like the adult tree. But surely every oak tree
is a successful acorn. Acorn and oak tree are just stages in one
organism, in the same organism, and that's the basis of something
like genetic intervention.
If you intervene in the acorn, it's because you want to get
an oak of a certain sort. So that's the continuity argument,
it seems to me, really translates into sameness for one specific
acorn and one specific oak tree.
Now, the question of the dignity, again, is different. I think
that, of course, we can have something like analogs to dignity.
CHAIRMAN KASS: I wasn't asserting that an oak tree
has dignity, but on hypothesis I—
DR. GÓMEZ-LOBO: The hypothesis that you treated—let's leave the word "dignity" out. Let's say
you treat the oak tree as having a certain high worth, a certain
CHAIRMAN KASS: Yes. But is the argument by analogy that
its germ has comparable worth? That was the only point. And the
answer I suppose is that's a dumb question, or—
DR. GÓMEZ-LOBO: No, it's a very appropriate
question. But again, I have to modify the hypothesis.
CHAIRMAN KASS: Okay.
DR. GÓMEZ-LOBO: Because the reason why we respect
an oak tree I think is very different from why we respect a human
being. But, you see, it's linked to the state of the oak tree
as an adult, and that's why it doesn't—the analogy is
a disanalogy. Now -
CHAIRMAN KASS: We'll fight about it.
DR. GÓMEZ-LOBO: Okay. Anytime. Anytime, anyplace.
CHAIRMAN KASS: It's not accepted as a reasonable example
without further discussion. I'm not surprised.
DR. GÓMEZ-LOBO: Okay. But you did accept my last
point that the reason we have not to cut down an oak tree is intimately
linked to its state in which it finds itself?
CHAIRMAN KASS: No.
DR. GÓMEZ-LOBO: No. Okay. Well, we'll fight
CHAIRMAN KASS: We'll argue later.
Look, we have only one person requesting to make public comment—Andrew Sperling from the National Alliance for the Mentally Ill.
And I think we should just go and have the public comment, and then
we will adjourn.
Mr. Sperling, the floor is yours.
Oh, excuse me. You know what the problem is? We are obliged—the public comment session I think is scheduled to begin at 11:30.
I make it 11:26, 25, and technically I'm not allowed to open
the public session before that time. So—
PROF. GEORGE: Do you want to do oak trees for four minutes?
DR. KRAUTHAMMER: No. No, no. Spare us.
PROF. SANDEL: Well, if it's oak trees, I will tell
them to hold the flight.
CHAIRMAN KASS: You're excused.
PROF. SANDEL: I don't want to miss anything good.
CHAIRMAN KASS: How can we guarantee that it will be good?
Take your chances.
DR. KRAUTHAMMER: Well, about the embryo and the parents—
CHAIRMAN KASS: Does someone have—could that be Mr. Sperling?
PROF. BLACKBURN: I have a suggestion.
CHAIRMAN KASS: Yes.
PROF. BLACKBURN: The oak tree has had a large journey
and a long history, which distinguishes it from the acorn in the
same way an adult human has had a long history and a large journey
to go through and all of that associated with it in a social context.
DR. GÓMEZ-LOBO: Sure. It has a long journey, but
don't oak trees come from an acorn?
CHAIRMAN KASS: That was what I was trying to get you to
say. But, you know, just as many embryos are called, few are chosen.
So many acorns, so few oak trees.
DR. GÓMEZ-LOBO: That's a sophistical argument.
CHAIRMAN KASS: No, no, no. I mean, that is to say there
being a—and since you never know which of these acorns might become
the oak tree, just as you never know which of the embryos will in
fact survive, you will—you are inclined to accord full respect
to every embryo.
DR. GÓMEZ-LOBO: Sure. But, you see, the problem—and I argued it in my paper—is that non-viability or the fact
that an organism can be destroyed along the way does not affect
CHAIRMAN KASS: Okay.
DR. GÓMEZ-LOBO: I mean, we respect a certain organism
because of its nature, not because of the chances.
CHAIRMAN KASS: Well, then, the question -
DR. GÓMEZ-LOBO: See, that's the confusion in
these discussions. People confuse potentiality with mere chance
of making it viability.
CHAIRMAN KASS: Very good. Now, I'm corrected, but
then it seems to me you should want to say that whatever the worth
of the oak tree, such is also the worth of the acorn.
PROF. GEORGE: No, you don't have to say that for this
reason. Everything depends on why we accord worth to the object.
In the case of the human being, what Alfonso argues and what I argue
is that the human being has dignity in virtue of the kind of entity
With the oak tree, we're not worried about its worth in virtue
of the kind of thing it is. We're interested in its—
CHAIRMAN KASS: Why not?
PROF. GEORGE: Well, for the same reason that we distinguish
an oak tree, a full adult oak tree, from a sapling. We're not—we don't care a whole lot about a sapling. Leave acorns out
CHAIRMAN KASS: You don't care about the weakest amongst
PROF. GEORGE: We certainly care about children, and we
don't distinguish the child, even the infant child, from the
mature adult, even if he has the intellectual capacity of Albert
Einstein or the skill of a great quarterback, or something like
And what that I think reveals is that we're interested in
the oak tree by virtue of the beauty of the oak tree, its extraordinary
magnificence, not in virtue of the kind of thing it is, because
it's the same kind of thing that the sapling is, and the same
kind of thing, at least as I understand the botany, that the acorn
Contrast that with the human being, if we hold, which I believe
we should, which I believe you do, that the dignity of the human
being has to do with the kind of thing it is and not its magnificence,
not its—not the brilliance of Albert Einstein, not the skill of
the adult quarterback, and that the infant at least has it just
as much as Albert Einstein does.
CHAIRMAN KASS: I don't think you could accept—I
don't think you can exempt kind from fullness altogether. But
that's a long—
PROF. GEORGE: Don't we do that in the case of the
infant child and Albert Einstein?
CHAIRMAN KASS: Yes. But I don't think—well, I have
to think about this some more, but I would be disinclined to say
that—we have a certain kind of utilitarian view of nature, which
leads us to somehow accord it things rather than to say that it
has some kind of intrinsic worthiness.
And if you're willing to go that language, then it seems to
me—and this is not an intermediate respect or anything that's
going to get us, but I'm not sure that young lion cubs and the
mature adult are not somehow, by virtue of being the same kind,
equally dear. And that then pushes the argument back to the beginning,
and then I move to the plants and—
PROF. MEILAENDER: You think they're not equally dear,
or they are equally dear?
CHAIRMAN KASS: I think they are.
PROF. SANDEL: To each other. However dear they are, they
are equally dear to each other.
DR. MCHUGH: Can a doctor jump in here for just a minute
and tell you why I hate this word "dignity."
I hate it. I've seen the use of the word "dignity"
being used to do all kinds of crimes. We're going to live with
dignity or die with dignity, or whatever with dignity, and I'm
finished with that word because I've seen it in killer's
What I want to acknowledge is the endowed nature of the kind that
is human beings. I want to go back to our founding document. We
are endowed by our creator with certain inalienable things, and
these things include the right to life. And that right to life
begins, in my opinion, with the zygote, not with the clonote.
CHAIRMAN KASS: We've had our commercial break. We've
made it exactly to 11:30 and the beginning of the public session.
And I have a suspicion that our little song-and-dance routine has
produced Mr. Sperling. If he is here, the microphone is yours,
Take a moment. I don't mean to rush you. But we finished
a few minutes early, and by law we have to wait until 11:30. And
I'm glad to have you here. Welcome to the Council.